SRD5A1-IN-1 |
| Catalog No.GC71193 |
SRD5A1-IN-1 (composé 4) est un inhibiteur concurrentiel et covalent de stéroïde 5α-réductase de type 1 (SRD5A1) avec une ci50 de 1,44 µM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2279077-93-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SRD5A1-IN-1 (Compound 4) (0.5-2.5 μM; 24 h) decreases SRD5A1 protein expression[1].
SRD5A1-IN-1 (0-2.5 μM; 12 h) modulates SRD5A1 via the dual actions that affect the level of SRD5A1 protein expression and the activity of the SRD5A1 enzyme[1].
References:
[1]. Lin A C K, et al. Caffeic acid N-[3, 5-bis (trifluoromethyl) phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics. Scientific Reports, 2022, 12(1): 1-20.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *